While the development and growth of prostate cancer can be inhibited by PPARγ agonists, stimulation of PPARγ may also directly lead to the carcinogenicity of prostate cancer via androgen receptor-dependent or -independent pathways (21). This evidence concerns the gene AR and prostate carcinoma.